Cancer researchers overestimate reproducibility of preclinical studies

Cancer scientists overestimate the extent to which high-profile preclinical studies can be successfully replicated, new research from McGill University suggests. Thes findings, published in PLOS Biology by Jonathan Kimmelman and colleagues from McGill, are based on a survey in which both experts and novices were asked to predict whether mouse experiments in six prominent preclinical cancer studies conducted by the Reproducibility Project: Cancer Biology (RP:CB) would reproduce the effects observed in original studies.

On average, the researchers forecasted a 75% probability of replicating statistical significance, and a 50% probability of reproducing the same size effect as in the original study. Yet according to these criteria, none of the six studies already completed by the Reproducibility Project showed the same results previously reported.

One possible explanation for the optimism is that cancer scientists overestimate the replicability of major reports in their field. Another is that they underestimate the logistical and methodological complexity of independent laboratories repeating these techniques.

Reproducibility crisis
The work follows on numerous reports exploring biomedicine's so-called reproducibility crisis. In the last 10 or 15 years, there have been mounting concerns that some of the techniques and practices used in biomedical research lead to inaccurate assessments of a drug's clinical promise.

Given that not all studies reproduce, Kimmelman and his team wondered if cancer experts could at least sniff out which studies would not easily replicate. The finding that cancer researchers' ability to do so "was really limited" suggests that there may be inefficiencies in the process by which science "self-corrects."

There is however strong community concern that, due to process-related issues and potential methodological differences, the replication studies themselves may not be an entirely reliable measure of replication outcome. Kimmelman emphasizes that the findings don't indicate that scientists who participated in the study don't understand what's going on their field -- nor does it diminish the importance of funding research and making policy on the basis of scientific consensus. Some scientists were highly accurate in their predictions, and participants were new to forecasting, which is difficult.

Training could be part of the solution
The results do, however, raise the possibility that training might help many scientists overcome certain cognitive biases that affect their interpretation of scientific reports.

"If the research community believes a finding to be reliable, it might start building on that finding only to later discover the foundations are rotten. If scientists suspect a claim to be spurious, they are more likely to test that claim directly before building on it."

"This is the first study of its type, but it warrants further investigation to understand how scientists interpret major reports," Kimmelman says. "I think there is probably good reason to think that some of the problems we have in science are not because people are sloppy at the bench, but because there is room for improvement in the way they interpret findings."

Benjamin D, Mandel DR, Kimmelman J.
Can cancer researchers accurately judge whether preclinical reports will reproduce?
PLoS Biol. 2017 Jun 29;15(6):e2002212. doi: 10.1371/journal.pbio.2002212.

Most Popular Now

FDA approves first biosimilar for the treatment of…

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvas...

Merck set to join forces with Project Data Sphere …

Merck, a leading science and technology company has announced that it will enter into a strategic collaboration with Project Data Sphere LLC, an independent, not-for-prof...

FDA approval brings first gene therapy to the Unit…

The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treat...

Boehringer Ingelheim Pharmaceuticals, Inc. receive…

Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled sy...

Asthma medicine halves risk of Parkinson's

Parkinson's disease is a chronic disease with unknown causes. The disease destroys the brain cells that control body movements. Shivering, stiff arms and legs and poor co...

This is how belly fat could increase your cancer r…

It's been well established that obesity is a contributor to cancer risk, but how it actually causes cancer is still a question that hasn't been fully explained. A new Mic...

Sanofi and Regeneron announce that cemiplimab (REG…

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to cemipli...

Tezepelumab significantly reduced asthma exacerbat…

AstraZeneca and Amgen Inc. (Amgen) announce results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation ...

Boehringer Ingelheim initiates Phase IIa study of …

Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NAS...

'Exciting' discovery on path to develop new type o…

Scientists at the University of Southampton have made a significant discovery in efforts to develop a vaccine against Zika, dengue and Hepatitis C viruses that affect mil...

Victoza® reduces the risk of major cardiovascular …

A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high ...

Researchers discover new immunotherapy combination…

Immunotherapy is an emerging field in the global fight against cancer, even though scientists and clinicians have been working for decades to find ways to help the body's...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]